The Future of TB Testing
.jpeg)
SIILTIBCY® is indicated in the EU as a medicinal product to aid the diagnostic detection of M. Tuberculosis infection during disease for children and adults aged 28 days or older.
1st in class rdESAT-6 and rCFP-10 containing skin test
high specificity and sensitivity in a field-friendly format
Did
you
know?
In 2022, TB was the 2nd leading infectious disease killer worldwide after COVID-19
In 2022, 10.6 million people fell ill with TB worldwide.
75 million lives have been saved since year 2000 due to global efforts to combat TB
USD 13 Billion required in 2023 for TB diagnostics and care
EU & Tuberculosis: an unending battle.
The WHO European Region faces important challenges in its struggle against TB. The major constraints are:
-
the high rate of multidrug-resistant TB (MDR-TB), mostly in the countries of the former USSR;
-
the rapid growth of the HIV epidemic in eastern countries and central Asia and consequently the sharp increase in HIV-related TB;
-
the need to reform the health sector to include closer involvement of primary health care in TB control;
-
the still limited political and financial commitment to TB control;
-
lack of advocacy, communication and social mobilization.
Need for new test options
" SIILTIBCY marks a vital progression in the battle against tuberculosis by enhancing diagnostic capabilities. This advancement supports public health initiatives and aligns with global efforts to eliminate TB."
NEWS: European Commission Grants Marketing Authorisation for SIILTIBCY® – A Novel Tuberculosis Skin Test in Europe
Pune (India) - Hannover (Germany) – Bilthoven (The Netherlands), February, 2025 – Serum Institute of India Pvt. Ltd. (SIIPL), a global leader in the vaccine manufacturing, along with its sister companies SLS Europe (Serum Life Science Europe GmbH) and BBio (Bilthoven Biologicals), which are part of the Cyrus Poonawalla Group, announce that SIILTIBCY®, a novel tuberculosis (TB) diagnostic test, has received full marketing authorisation from the European Commission (EC). This authorisation is based on a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP).